From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]
  • US: C (Risk not ruled out)
Routes of
Legal status
Legal status
Pharmacokinetic data
Bioavailability Absorbed systemically, but below detectable levels (less than 10 ng/mL)
Protein binding ~60%
Biological half-life 111 days
Excretion Renal (60%)
CAS Number 138890-62-7
ATC code S01EC04 (WHO)
PubChem CID 68844
DrugBank APRD00475
ChemSpider 62077
Chemical data
Formula C12H21N3O5S3
Molar mass 383.51 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Brinzolamide (trade name Azopt, Alcon Laboratories, Inc.) is a carbonic anhydrase inhibitor used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.


Brinzolamide is a carbonic anhydrase inhibitor (specifically, carbonic anhydrase II). Carbonic anhydrase is found primarily in erythrocytes (but also in other tissues including the eye). It exists as a number of isoenzymes, the most active of which is carbonic anhydrase II (CA-II).


Use for the treatment of open-angle glaucoma and raised intraocular pressure due to excess aqueous humor production.


Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion and thus lowers the intraocular pressure in the anterior chamber, presumably by reducing the rate of formation of bicarbonate ions with subsequent reduction in sodium and fluid transport; this alleviates the effects of open-angle glaucoma.



The recommended frequency for topical application is three times per day. Following ocular instillation, the suspension is systemically absorbed to some degree; however the plasma concentrations are low and generally below the limits of detection (less than 10 ng/mL) due to extensive binding by tissues and erythrocytes. Oral administration is less-favored due to variable absorption from the stomach mucosa and an increased side-effect profile versus ophthalmic administration.


The compound is fairly well protein-bound (60%), but adheres extensively to the carbonic anhydrase-containing erythrocytes. Due to the abundance of readily-bound erythrocytes and minimal known metabolism, Brinzolamide's whole blood half-life is very long (111 days).


While definitive sites of metabolism have not been firmly established, there are several metabolites worthy of note. N-Desethylbrinzolamide is an active metabolite of the parent compound, and thus exhibits carbonic anhydrase inhibitory activity (largely carbonic anhydrase-I, when in the presence of Brinzolamide) and also accumulates in the erythrocytes. However, Brinzolamide's other known metabolites (N-Desmethoxypropylbrinzolamide and O-Desmethylbrinzolamide) either have no activity or their activity is currently unknown.


Brinzolamide is excreted primarily unchanged (60%) in the urine, although the renal clearance rate has not been definitively determined. N-Desethylbrinzolamide is also found in the urine along with lower concentrations of the inactive metabolites, N-Desmethoxypropylbrinzolamide and O-Desmethylbrinzolamide; exact levels have not been definitively determined.


Side effects

  • Common, but mild: Blurred vision; bitter, sour, or unusual taste; itching, pain, watering, or dryness of the eyes; feeling that something is in the eye; headache; runny nose
  • Rare, but serious: Fast or irregular heartbeat; fainting; skin rash, hives, or itching; severe eye irritation, redness, or swelling; swelling in the face, lips, or throat; wheezing or trouble breathing


  • Hypersensitivity to other sulfonamides
  • Acute angle-closure glaucoma
  • Concomitant administration of oral carbonic anhydrase inhibitors
  • Moderate-to-severe renal or hepatic insufficiency

Combination with timolol

The combination of brinzolamide with timolol is marketed under the trade name Azarga. Clinical studies have shown this combination to be more effective than either of the medications taken as monotherapy.[1]


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
  • Ermis S, Ozturk F, Inan U (2005). "Comparing the effects of travoprost and brinzolamide on intraocular pressure after phacoemulsification". Eye. 19 (3): 303–7. doi:10.1038/sj.eye.6701470. PMID 15258611. 
  • Iester M, Altieri M, Michelson G, Vittone P, Traverso C, Calabria G (2004). "Retinal peripapillary blood flow before and after topical brinzolamide". Ophthalmologica. 218 (6): 390–6. doi:10.1159/000080942. PMID 15564757. 
  • Kaup M, Plange N, Niegel M, Remky A, Arend O (2004). "Effects of brinzolamide on ocular haemodynamics in healthy volunteers". Br J Ophthalmol. 88 (2): 257–62. doi:10.1136/bjo.2003.021485. PMC 1771998Freely accessible. PMID 14736787. 
  • March WF, Ochsner KI (2000). "The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension". Am J Ophthalmol. 129 (2): 136–143. doi:10.1016/S0002-9394(99)00343-8. PMID 10682964. 
  • Product Information: Azopt(R), brinzolamide. Alcon Laboratories, Inc, Fort Worth, TX, 1998b.
  • Sall KN, Greff LJ, Johnson-Pratt LR, et al.: Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology 2003; 110:615-624.


  1. Croxtall JD, Scott, LJ.[1].Drugs&Aging 2009;26(5):437-446.doi: 10.2165/00002512-200926050-00007.